Trial
NCT05156229
A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Codiak BioSciences
Collaborators
—
Condition
Cutaneous T-cell Lymphoma (CTCL)
Intervention
CDK-003
Why stopped
PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety profile. Proceeding to Phase II did not require additional data from this Phase I Dose-Finding study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-02